Search - tctmd.com

Displaying 141 - 160 of 210

Sort: Relevancy | Date

Presentation TCT 2018

TCT-98: Early Clinical Impact of Cerebral Embolic Protection With Transcatheter Aortic Valve Replacement, a Multicenter Study in the Netherlands

Presenter: Alain G. Cribier, Helene Eltchaninoff, Herbert Kroon

September 21, 2018

Presentation TCT 2018

TCT-88: Optimal Cerebral Protection in Cardiac and Aortic Interventions: Vascular Filters vs. Balloon Occlusion?

Presenter: Jacques Busquet, Virendra I Patel, Michael Zhadkevich

September 21, 2018

News Conference News ESC 2018

TAVR Debris Captured by Sentinel Embolic Protection Differs by Valve Type

Yael L. Maxwell

September 06, 2018

News Industry News

Boston Scientific Announces Agreement to Acquire Claret Medical, Inc.

July 24, 2018

News Daily News

Sentinel Cerebral Embolic Protection Device Acquired by Boston Scientific

Shelley Wood

July 20, 2018

News Conference News The Structural Heart Disease Summit 2018

Data or Money: What’s Holding Back Cerebral Embolic Protection in TAVR?

Shelley Wood

June 21, 2018

Presentation The Structural Heart Disease Summit 2018

NO: The Data Are Weak and the Costs Are Prohibitive!

Presenter: John K. Forrest

June 21, 2018

Presentation The Structural Heart Disease Summit 2018

YES: Review of ALL the Data and Common Sense Tell the Story!

Presenter: Axel Linke

June 21, 2018

Presentation The Structural Heart Disease Summit 2018

Keystone TRIGUARD Cerebral Embolic Protection During TAVR: New Generation Devices and the Status of Ongoing Clinical Trials

Presenter: Eberhard Grube, Tamim Nazif

June 21, 2018

Presentation The Structural Heart Disease Summit 2018

Cedars-Sinai Medical Center (USA)

Presenter: Tarun Chakravarty

June 21, 2018

Presentation The Structural Heart Disease Summit 2018

Erasmus University (The Netherlands)

Presenter: Nicolas M. Van Mieghem

June 21, 2018

Presentation The Structural Heart Disease Summit 2018

Ulm University (Germany)

Presenter: Julia Seeger

June 21, 2018

Presentation The Structural Heart Disease Summit 2018

Cost-effectiveness of Cerebral Protection During TAVR: Can We Justify Systematic Use?

Presenter: Eberhard Grube, Tamim Nazif, Hemal Gada

June 21, 2018

Presentation The Structural Heart Disease Summit 2018

Strokes After Transfemoral TAVR vs SAVR: A Propensity-Matched Analysis From the PARTNER Trial

Presenter: Eberhard Grube, Tamim Nazif, Chetan P. Huded

June 21, 2018

Presentation The Structural Heart Disease Summit 2018

Strokes After TAVR (and SAVR): Incidence in the "Modern Era" and Key Messages From NeuroARC

Presenter: Eberhard Grube, Tamim Nazif, Alexandra J. Lansky

June 21, 2018

News Conference News EuroPCR 2018

Embolic Protection in TAVR: Signs of Benefit, but Road Map for Use Still Uncharted

Caitlin E. Cox

May 23, 2018

News Conference News EuroPCR 2018

EuroPCR 2018: Stable CAD, Functional Tests, and Renal Denervation Take Center Stage

Shelley Wood

May 17, 2018

Presentation SCAI 2018

Cerebral Embolic Protection: Protect Everyone

Presenter: Samir Kapadia

April 28, 2018

Presentation SCAI 2018

Unresolved Issues: Cerebral Embolic Protection Use Selectively!

Presenter: Steven J Yakubov

April 28, 2018

News Conference News SCAI 2018

Debate Over Cerebral Protection in TAVR Fizzles in the Face of Reimbursement Hopes

Shelley Wood

April 28, 2018

Advertisement

TCT-98: Early Clinical Impact of Cerebral Embolic Protection With Transcatheter Aortic Valve Replacement, a Multicenter Study in the Netherlands

TCT-88: Optimal Cerebral Protection in Cardiac and Aortic Interventions: Vascular Filters vs. Balloon Occlusion?

TAVR Debris Captured by Sentinel Embolic Protection Differs by Valve Type

Boston Scientific Announces Agreement to Acquire Claret Medical, Inc.

Sentinel Cerebral Embolic Protection Device Acquired by Boston Scientific

Data or Money: What’s Holding Back Cerebral Embolic Protection in TAVR?

NO: The Data Are Weak and the Costs Are Prohibitive!

YES: Review of ALL the Data and Common Sense Tell the Story!

Keystone TRIGUARD Cerebral Embolic Protection During TAVR: New Generation Devices and the Status of Ongoing Clinical Trials

Cedars-Sinai Medical Center (USA)

Erasmus University (The Netherlands)

Ulm University (Germany)

Cost-effectiveness of Cerebral Protection During TAVR: Can We Justify Systematic Use?

Strokes After Transfemoral TAVR vs SAVR: A Propensity-Matched Analysis From the PARTNER Trial

Strokes After TAVR (and SAVR): Incidence in the "Modern Era" and Key Messages From NeuroARC

Embolic Protection in TAVR: Signs of Benefit, but Road Map for Use Still Uncharted

EuroPCR 2018: Stable CAD, Functional Tests, and Renal Denervation Take Center Stage

Cerebral Embolic Protection: Protect Everyone

Unresolved Issues: Cerebral Embolic Protection Use Selectively!

Debate Over Cerebral Protection in TAVR Fizzles in the Face of Reimbursement Hopes

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content